Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.
The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.
Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.
Blueprint Medicines' increased debt brings a heightened risk profile due to last year's dilution in revenues and lack of profitability. Its future earnings and balance sheet health are key to assessing risk.
Significant sale by President of R&D Fouad Namouni implies shares may not be undervalued. This, along with multiple insider sales, is a potential red flag for investors.
The significant fall in both the share price and revenue of Blueprint Medicines Corporation could indicate unresolved issues within the company. The continued lack of profitability may also be a concern for long-term investors.
Blueprint Medicines股票討論區
Extended Hours Top Moovers.
📊⚡️📊
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$默沙東(MRK.US)$ x $Immunovant(IMVT.US)$
$禮來(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元製藥公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科學(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施貴寶(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$禮來(LLY.US)$ x $Merus(MRUS.US)$ (partner n...
美國東部時間11月10日上午8點10分,“Blueprint Medicines獲得CHMP對艾瓦基特的正面評價
專欄Top upgrades and downgrades on 7/8: PYPL, UPST, AAL, RCKT and more
• $Vita Coco(COCO.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $12 (from $10)
• $Diebold Nixdorf(DBD.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $5
• $Eversource Energy(ES.US)$ : Guggenheim Upgrades to Buy from Neutral - PT $97 (from $92)
• $Howmet Aerospace(HWM.US)$ : Benchmark Upgrades to Buy from Neutral - PT $40
• $埃培智(IPG.US)$ : Wells Fargo Upgrades to Overweight...
暫無評論